All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of a reduced starting dose of ruxolitinib on survival in patients with MF
Bookmark this article
|
A retrospective analysis of a prospective observational cohort from AIFA Monitoring Registries assessed the association between the starting dose of ruxolitinib, an oral JAK1/2 inhibitor, and long-term outcomes in 3,494 patients with MF.1 Results from this analysis were published in the British Journal of Haematology by Breccia et al.1 |
| Key learnings |
| Patients initiating ruxolitinib at reduced doses (n = 2,337) were generally older, with larger splenomegaly, higher IPSS risk, and worse ECOG scores. |
| After balancing for baseline characteristics, initiating ruxolitinib at a reduced dose was associated with a shorter median OS (52.6 months vs. 78.2 months; HR, 1.444; 95% CI, 1.296–1.609; p <0.001) compared with starting at the full dose. |
| Subgroup analysis indicated that the reduced starting dose affected OS in patients with intermediate-2 (HR, 1.491; 95% CI, 1.294–1.718; p <0.001) and high (HR, 1.398; 95% CI, 1.176–1.66; p <0.001) IPSS risk. |
| These findings show that, regardless of the baseline characteristics, a reduced starting dose of ruxolitinib was associated with worse survival outcomes in patients with intermediate-2 and high-risk MF. |
Abbreviations: AIFA, Agenzia Italiana del Farmaco; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IPSS, International Prognostic Scoring System; JAK, Janus kinase; MF, myelofibrosis; OS, overall survival.
- Breccia M, Celant S, Palandri F, et al. The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries. Br J Haematol. 2024. Online ahead of print. DOI: 10.1111/bjh.19812
More about...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox